30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Virus-like particles: Passport to immune recognition

      research-article
      * ,
      Methods (San Diego, Calif.)
      Elsevier Inc.
      Virus-like particles, Vaccine, Chimeric VLPs

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Virus-like particles (VLPs) are formed by the self-assembly of envelope and/or capsid proteins from many viruses. In many cases such VLPs have structural characteristics and antigenicity similar to the parental virus, and some have already proven successful as vaccines against the cognate virus infection. The structural components of some VLPs have also proven amenable to the insertion or fusion of foreign antigenic sequences, allowing the production of chimeric VLPs exposing the foreign antigen on their surface. Other VLPs have been used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. This review outlines some of the advantages, disadvantages, and technical considerations for the use of a wide range of VLP systems in vaccine development.

          Related collections

          Author and article information

          Contributors
          Journal
          Methods
          Methods
          Methods (San Diego, Calif.)
          Elsevier Inc.
          1046-2023
          1095-9130
          22 September 2006
          September 2006
          22 September 2006
          : 40
          : 1
          : 60-65
          Affiliations
          Macfarlane Burnet Institute for Medical Research and Public Health, 85 Commercial Road, Melbourne 3004, Australia
          Author notes
          [* ]Corresponding author. Fax: +61 3 9282 2100. grgacic@ 123456burnet.edu.au
          Article
          S1046-2023(06)00162-9
          10.1016/j.ymeth.2006.07.018
          7128828
          16997714
          a2bd2575-92c1-44d6-aa13-5313f2b7c3bd
          Copyright © 2006 Elsevier Inc. All rights reserved.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 20 July 2006
          Categories
          Article

          Life sciences
          virus-like particles,vaccine,chimeric vlps
          Life sciences
          virus-like particles, vaccine, chimeric vlps

          Comments

          Comment on this article